GEPA43001
Cy®3-Streptavidin
Cytiva PA43001
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
UNSPSC-Code:
12352203
NACRES:
NA.46
Empfohlene Produkte
Form
solid
Verpackung
pkg of 1 mg
Hersteller/Markenname
Cytiva PA43001
Farbe
Blue
Lagertemp.
2-8°C
Verwandte Kategorien
Allgemeine Beschreibung
Cy3-Streptavidin
Cy3-Streptavidin
Cy3-Streptavidin
- Streptavidin conjugated to a range of fluorescent dyes for use in in situ hybridization and flow cytometry.
- High specificity reagents.
Anwendung
Suitable for use in the fluorescent analysis of biotinylated samples.
Leistungsmerkmale und Vorteile
- Streptavidin conjugated to a range of fluorescent dyes for use in in situ hybridization and flow cytometry.
- High specificity reagents.
- Convenient: no need to label in-house
- Streptavidin conjugated to Cy2, Cy3, or C5 fluorescent dyes
Lagerung und Haltbarkeit
Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.
Hinweis zur Analyse
To view the Certificate of Analysis for this product, please visit www.cytiva.com.
Rechtliche Hinweise
CyDye:
Cy3B: This product is manufactured under an exclusive license from Carnegie Mellon University and is covered by US patent number 6,133,445 and equivalent patents and patent applications in other countries.
CyQ (or Cy5Q or Cy7Q): These products are covered under US patent number 6,828,116 and equivalent patents and patent applications in other countries in the name of Cytiva.
CytoCy5S: The use of this product in an NTR gene reporter assay is the subject of US patent number 7,579,140 in the name of Cytiva.
CypHer5E: This product or portions thereof is manufactured under license from Carnegie Mellon University and is covered by US patent number 7,615,646.
Cy and CyDye, are - trademarks of Cytiva or one of its subsidiaries.
The purchase of CyDye products includes a limited license to use the CyDye products for internal research and development but not for any commercial purposes. A license to use the Cy and CyDye trademarks for commercial purposes is subject to a separate license agreement with Cytiva. Commercial use shall include:
1. Sale, lease, license or other transfer of the material or any material derived or produced from it.
2. Sale, lease, license or other grant of rights to use this material or any material derived or produced from it.
3. Use of this material to perform services for a fee for third parties, including contract research and drug screening.
If you require a commercial license to use the Cy and CyDye trademarks please contact LSlicensing@cytiva.com.
If you require a commercial license to use this material and do not have one, return this material unopened to Cytiva Bio-Sciences AB, Bjorkgatan 30, SE-751 84 Uppsala, Sweden and any money paid for the material will be refunded.
Cy3B: This product is manufactured under an exclusive license from Carnegie Mellon University and is covered by US patent number 6,133,445 and equivalent patents and patent applications in other countries.
CyQ (or Cy5Q or Cy7Q): These products are covered under US patent number 6,828,116 and equivalent patents and patent applications in other countries in the name of Cytiva.
CytoCy5S: The use of this product in an NTR gene reporter assay is the subject of US patent number 7,579,140 in the name of Cytiva.
CypHer5E: This product or portions thereof is manufactured under license from Carnegie Mellon University and is covered by US patent number 7,615,646.
Cy and CyDye, are - trademarks of Cytiva or one of its subsidiaries.
The purchase of CyDye products includes a limited license to use the CyDye products for internal research and development but not for any commercial purposes. A license to use the Cy and CyDye trademarks for commercial purposes is subject to a separate license agreement with Cytiva. Commercial use shall include:
1. Sale, lease, license or other transfer of the material or any material derived or produced from it.
2. Sale, lease, license or other grant of rights to use this material or any material derived or produced from it.
3. Use of this material to perform services for a fee for third parties, including contract research and drug screening.
If you require a commercial license to use the Cy and CyDye trademarks please contact LSlicensing@cytiva.com.
If you require a commercial license to use this material and do not have one, return this material unopened to Cytiva Bio-Sciences AB, Bjorkgatan 30, SE-751 84 Uppsala, Sweden and any money paid for the material will be refunded.
Cy is a registered trademark of Cytiva
Signalwort
Danger
H-Sätze
Lagerklassenschlüssel
13 - Non Combustible Solids
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Kunden haben sich ebenfalls angesehen
Aiping Lu et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 35(3), e21378-e21378 (2021-02-11)
The decline of muscle regenerative potential with age has been attributed to a diminished responsiveness of muscle progenitor cells (MPCs). Heterochronic parabiosis has been used as a model to study the effects of aging on stem cells and their niches.
P Grigaravicius et al.
Cell death and differentiation, 23(3), 454-468 (2015-09-19)
Endoplasmic reticulum (ER) stress, defective autophagy and genomic instability in the central nervous system are often associated with severe developmental defects and neurodegeneration. Here, we reveal the role played by Rint1 in these different biological pathways to ensure normal development
Aiping Lu et al.
Scientific reports, 10(1), 7075-7075 (2020-04-29)
Duchenne muscular dystrophy (DMD) is a progressive muscle disease, characterized by mutations in the X-linked dystrophin, that has several therapeutic options but no curative treatment. Transplantation of muscle progenitor cells for treatment of DMD has been widely investigated; however, its application is
Aiping Lu et al.
Human molecular genetics, 23(18), 4786-4800 (2014-05-02)
Duchenne muscular dystrophy (DMD) patients lack dystrophin from birth; however, muscle weakness becomes apparent only at 3-5 years of age, which happens to coincide with the depletion of the muscle progenitor cell (MPC) pools. Indeed, MPCs isolated from older DMD
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.